This page catalogs biotechnology and pharmaceutical companies developing therapeutics targeting the Notch signaling pathway and gamma-secretase for [Alzheimer's disease](/diseases/alzheimers-disease). The Notch pathway has emerged as a critical regulator of amyloid precursor protein (APP) processing and neurodegenerative processes through its roles in neural development, synaptic plasticity, and cellular stress responses["@lasky2020"]. In AD, Notch signaling intersects with key pathological processes including amyloid-beta production, tau phosphorylation, neuroinflammation, and synaptic dysfunction.
Gamma-secretase is a central enzyme in AD pathogenesis as it performs the final cleavage of APP to produce amyloid-beta peptides. While gamma-secretase inhibitors have shown preclinical promise, selective Notch modulation and gamma-secretase modulation represent promising alternative approaches that may preserve essential cellular functions while providing therapeutic benefit["@bittner2016"].
The Notch family consists of four receptors (Notch1-4) and multiple ligands (Jagged1, Jagged2, DLL1, DLL3, DLL4). In AD, Notch signaling plays several important roles[@wang2014]:
Gamma-secretase is a proteolytic enzyme complex (comprising PSEN1/Presenilin-1, PSEN2/Presenilin-2, NCT/ Nicastrin, and APH-1a/b) that cleaves over 100 substrates including APP and Notch receptors[@schliebs2012]. While gamma-secretase inhibitors (GSIs) have shown preclinical promise for reducing amyloid-beta production, they face significant challenges:
GSMs represent a distinct class of compounds that:
Status: Phase 1 Program: YH-4001 - Gamma-secretase modulator
Yuhan Corporation is developing YH-4001, a gamma-secretase modulator targeting APP processing in Alzheimer's disease. The modulator approach shifts processing away from amyloid-beta peptide production while preserving essential Notch signaling and other vital functions[@chen2019].
Mechanism: Modulation of gamma-secretase activity to reduce Aβ42/Aβ40 production while maintaining non-amyloidogenic processing.
Clinical Status: Phase 1 clinical trials in Alzheimer's disease.
See also: [Yuhan Corporation](/companies/yuhan-corporation) - for complete company profile
Status: Research Stage Program: MK-0752 and related Notch/gamma-secretase inhibitors
Merck has developed MK-0752, a potent gamma-secretase inhibitor that has been evaluated in clinical trials for oncology. Research has explored repurposing MK-0752 and related compounds for neurodegenerative diseases including AD.
Mechanism: Gamma-secretase inhibition reduces amyloid-beta production through complete enzyme inhibition.
Development Status: Research stage for AD; no active clinical trials in AD as of 2024.
Status: Research Stage Program: Notch pathway modulators
Bristol-Myers Squibb has explored Notch signaling modulators in the context of cancer and inflammatory diseases. While not actively developing AD-specific programs, the company has contributed to understanding Notch biology that informs neurodegeneration research.
Relevant Research: BMS-906039 is a pan-Notch inhibitor investigated in oncology, used in research to understand Notch-APP interactions.
Status: Phase 2b Program: Varoglutamstat (PQ912) - Glutaminyl Cyclase Inhibitor
While not directly a Notch/gamma-secretase modulator, varoglutamstat represents an innovative approach that works upstream of amyloid-beta by inhibiting glutaminyl cyclase, which catalyzes the formation of pyroglutamate-modified Aβ (pGlu-Aβ), a particularly toxic variant.
Mechanism: Inhibition of glutaminyl cyclase prevents formation of pGlu-Aβ, which acts as a seed for amyloid aggregation.
Clinical Status: Phase 2b VIVIAD trial in early AD.
See also: [Vivoryon Therapeutics](/companies/vivoryon) - for complete company profile
Status: Preclinical/Research Program: LRRK2 inhibitors with APP processing considerations
While Denali's primary focus is on LRRK2 inhibition for Parkinson's disease, their research program considers pathway interactions between LRRK2 and amyloid processing. Studies have shown that LRRK2 kinase activity can affect APP trafficking, providing potential opportunities for AD.
Development Status: Early-stage research exploring AD applications.
See also: [Denali Therapeutics](/companies/denali) - for complete company profile
Status: Research Program: Protein clearance pathways
Prothena has developed expertise in protein clearance mechanisms relevant to neurodegenerative diseases. While their lead programs target alpha-synuclein (prasinezumab) and tau, their research platform encompasses autophagy and protein quality control pathways that intersect with Notch signaling.
Relevant Research: Understanding of how Notch modulates autophagy-lysosomal pathways may inform future AD combination approaches.
Multiple academic centers have conducted preclinical research on Notch/gamma-secretase modulators for AD:
| Institution | Focus | Status |
|-------------|-------|--------|
| Massachusetts General Hospital | Notch regulation of BACE1 | Preclinical |
| University of Cambridge | GSM mechanism studies | Research |
| Johns Hopkins University | Notch-Aβ interactions | Preclinical |
| University of Pennsylvania | iPSC models of Notch dysregulation | Research |
| Company | Drug/Mechanism | Indication | Stage | Notes |
|---------|----------------|------------|-------|-------|
| Yuhan | YH-4001 (GSM) | AD | Phase 1 | Modulator approach |
| Merck | MK-0752 (GSI) | AD | Research | Repurposing potential |
| Vivoryon | Varoglutamstat (QCi) | AD | Phase 2b | pGlu-Aβ target |
| Denali | LRRK2 inhibitors | AD | Research | Pathway interactions |
| Prothena | Protein clearance | AD | Research | Autophagy modulators |
GSI = Gamma-Secretase Inhibitor GSM = Gamma-Secretase Modulator QCi = Glutaminyl Cyclase Inhibitor
The Notch pathway presents significant therapeutic challenges[@kelleher2015]:
Complete Notch/gamma-secretase inhibition may cause[@bittner2016]:
Optimal timing for Notch-targeted interventions:
Emerging strategies for Notch/gamma-secretase-targeted AD therapy:
Critical needs for clinical development:
Future directions include:
The following diagram shows the key molecular relationships involving Notch Signaling and Gamma-Secretase Modulators for Alzheimer's Disease discovered through SciDEX knowledge graph analysis: